5-羟基-3-甲氧基-2-甲基-6-戊基吡喃-4-酮 | 125263-70-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 中文名称: 5-羟基-3-甲氧基-2-甲基-6-戊基吡喃-4-酮
• 中文别名: 乙磺酸,2-氨基-,盐,钾聚合1,3-二(乙烯基磺酰)-2,2-二((乙烯基磺酰)甲基)丙烷
• 英文名称: allixin
• 英文别名: 5-hydroxy-3-methoxy-2-methyl-6-pentylpyran-4-one
• CAS: 125263-70-9
• 化学式: C₁₂H₁₈O₄
• 分子量: 226.273
• InChiKey: OHRPDNHRQKOLGN-UHFFFAOYSA-N

物化性质

• 物理描述：
  Solid
• 熔点：
  80-81°C

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(2,5-Dimethoxy-5-methylfuran-2-yl)hexan-1-ol 在 selenium(IV) oxide 、 对甲苯磺酸 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 5.5h， 生成 5-羟基-3-甲氧基-2-甲基-6-戊基吡喃-4-酮
  参考文献：
  名称：

  蒜素及其相关化合物的简便合成

  摘要：

  蒜素通过非常方便的方法合成，仅包括五个步骤。起始化合物为5-甲基糠醛，电化学氧化是该方法的关键步骤。

  DOI：

  10.1016/s0040-4039(98)00148-8

文献信息

• [EN] HYDROGEL-LINKED PRODRUGS RELEASING MODIFIED DRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À UN HYDROGEL LIBÉRANT DES MÉDICAMENTS MODIFIÉS
  申请人：ASCENDIS PHARMA AS

  公开号：WO2014173759A1

  公开（公告）日：2014-10-30

  The present invention relates to a process for the preparation of a hydrogel-linked prodrug releasing a tag moiety-bio logically active moiety conjugate, to a hydrogel-linked prodrug releasing a tag moiety-bio logically active moiety conjugate obtainable by such process, to pharmaceutical compositions comprising said prodrug and their use as a medicament.

  本发明涉及一种制备水凝胶连接的前药释放标签基团-生物活性基团结合物的方法，以及通过该方法获得的水凝胶连接的前药释放标签基团-生物活性基团结合物，还涉及包含该前药的药物组合物及其作为药物的用途。
• [EN] PRODRUGS OF HYDROXYL-COMPRISING DRUGS<br/>[FR] PROMÉDICAMENTS DE MÉDICAMENTS COMPRENANT DES GROUPES HYDROXYLE
  申请人：ASCENDIS PHARMA AS

  公开号：WO2013160340A1

  公开（公告）日：2013-10-31

  The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a biologically active moiety-linker conjugate D-L, wherein D is a hydroxyl-comprising biologically active moiety; and L is a promoiety comprising a moiety L1 represented by formula (I) and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L2 is a single chemical bond or a spacer and Z is a carrier group. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.

  本发明涉及一种前药或其药学上可接受的盐，包括生物活性基团-连接物D-L的共轭物，其中D是含有羟基的生物活性基团；L是包含由式(I)表示的基团L1的前基团，其中L1被一个到四个基团L2-Z取代，并且可选择进一步取代，前提是式(I)中带星号标记的氢未被取代；其中L2是一个化学键或一个间隔物，Z是一个载体基团。该发明还涉及包含所述前药的药物组合物及其作为药物的用途。
• Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
  申请人：Scaramuzzino, Giovanni

  公开号：EP1336602A1

  公开（公告）日：2003-08-20

  New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

  通式（I）的新药物化合物：F-（X）q，其中q是1到5的整数，最好是1；-F是在文本中描述的药物中选择的，-X是在文本中描述的4个组-M，-T，-V和-Y中选择的。通式（I）的化合物是硝酸盐前药，可以在体内以受控和选择性的方式释放一氧化氮，而不会产生降压副作用，因此它们非常适用于制备用于预防和治疗肌肉骨骼，皮肤，呼吸，消化，泌尿和中枢神经系统的炎症，缺血，退行性和增生性疾病的药物。
• Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels
  申请人：Rau Harald

  公开号：US20120156259A1

  公开（公告）日：2012-06-21

  The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament.

  本发明涉及可生物降解的聚乙二醇基水不溶性水凝胶，其包含通过水解降解键相互连接的骨架基团，骨架基团进一步包括反应性功能团，其中水不溶性水凝胶的特征在于，通过水解降解可将可降解键分解为可溶于水的降解产物，包括一个或多个骨架基团，完全降解水凝胶所需的时间与基于水凝胶中所有骨架基团数量的第一个10摩尔％可溶性降解产物的释放时间之比大于1且小于等于2。本发明还涉及这种水凝胶与配体或配位基团的共轭物、前药和制药组合物以及它们在药物中的使用。
• DRUG FOR AMELIORATING BRAIN DISEASES
  申请人：WAKUNAGA PHARMACEUTICAL CO., LTD.

  公开号：EP0838220A1

  公开（公告）日：1998-04-29

  The present invention discloses a drug for ameliorating brain diseases which comprises as an active ingredient a compound represented by the following formula (1): [wherein R1 represents H, OH, a lower alkoxyl group, or a lower alkyl group; each of R2 and R3 represents H, a (substituted) lower alkyl group, a lower alkenyl group, a (substituted) phenyl group, or a (substituted) styryl group; and X represents O or a nitrogen atom which may be substituted by a lower alkyl group] or a salt thereof. Because of inhibiting a decrease in brain neurons and promoting branching of neurites, this drug is efficacious in the prevention and treatment of dementia, etc. in association with degeneration and sloughing of brain neurons.

  本发明公开了一种用于改善脑部疾病的药物，其活性成分包括下式（1）所代表的化合物： [其中 R1 代表 H、OH、低级烷氧基或低级烷基；R2 和 R3 各代表 H、（取代的）低级烷基、低级烯基、（取代的）苯基或（取代的）苯乙烯基；X 代表 O 或可被低级烷基取代的氮原子]或其盐。由于这种药物能抑制脑神经元的减少并促进神经元的分枝，因此对预防和治疗与脑神经元退化和脱落有关的痴呆症等具有疗效。

表征谱图